Paul Canning

Paul Canning

Auto-generated profile, based on publicly available information

Paul Canning

Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, Belfast, UK

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2002 in Diabetes
Verified
Journal Article
Closed access
PDF file
Alan W StittAlan W Stitt
Alan W Stitt
TGThomas A. Gardiner
Thomas A. Gardiner
NANathan L. Anderson
Nathan L. Anderson
PCPaul Canning
Paul Canning
NFNorma Frizzell
Norma Frizzell
STSuzanne R. Thorpe
Suzanne R. Thorpe
We examined the ability of pyridoxamine (PM), an inhibitor of formation of advanced glycation end products (AGEs) and lipoxidation end products (ALEs), to protect against diabetes-induced retinal vascular lesions. The effects of PM were compared with the antioxidants vitamin E (VE) and R-α-lipoic acid (LA) in streptozotocin-induced diabetic rats. Animals were given either PM (1 g/l drinking water), VE (2,000 IU/kg diet), or LA (0.05%/kg diet). After 29 weeks of diabetes, retinas were examined for pathogenic changes, alterations in extracellular matrix (ECM) gene expression, and accumulation of the immunoreactive AGE/ALE Nε-(carboxymethyl)lysine (CML). Acellular capillaries were increased more than threefold, accompanied by significant upregulation of laminin immunoreactivity in the retinal microvasculature. Diabetes also increased mRNA expression for fibronectin (2-fold), collagen IV (1.6-fold), and laminin β chain (2.6-fold) in untreated diabetic rats compared with nondiabetic rats. PM treatment protected against capillary drop-out and limited laminin protein upregulation and ECM mRNA expression and the increase in CML in the retinal vasculature. VE and LA failed to protect against retinal capillary closure and had inconsistent effects on diabetes-related upregulation of ECM mRNAs. These results indicate that the AGE/ALE inhibitor PM protected against a range of pathological changes in the diabetic retina and may be useful for treating diabetic retinopathy.

1 October 2013 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
HGHong Guo-Parke
Hong Guo-Parke
PCPaul Canning
Paul Canning
IDIsobel Douglas
Isobel Douglas
RVRémi Villenave
Rémi Villenave
LHLiam G. Heaney
Liam G. Heaney
Ultan PowerUltan Power
Ultan Power
Rationale: Respiratory syncytial virus (RSV) is a major pathogen that primarily infects airway epithelium. Most infants suffer mild upper respiratory tract (URT) symptoms, whereas approximately one-third progress to lower respiratory tract (LRT) involvement. Despite the ubiquity of URT infection, little is known about the relative cytopathogenesis of RSV infection in infant URT and LRT. Objectives: This study aimed to compare RSV cytopathogenesis in nasal- and bronchial-derived epithelium from the same individuals using novel models derived from well-differentiated primary pediatric nasal (WD-PNECs) and bronchial epithelial cells (WD-PBECs). Methods: WD-PNECs and WD-PBECs were generated from nasal and bronchial brushes, respectively, and mock-infected or infected with RSV BT2a. RSV tropism, infectivity, cytopathology, growth kinetics, cell sloughing, apoptosis, and cytokine and chemokine responses were determined. Measurements and Main Results: RSV infection in both cultures was restricted to apical ciliated cells and occasional nonciliated cells but not goblet cells. It did not cause gross cytopathology. Infection resulted in apical release of progeny virus, increased apical cell sloughing, apoptosis, and occasional syncytia. RSV growth kinetics and peak titers were higher in WD-PBECs, coincident with higher ciliated cell contents, cell sloughing, and slightly compromised tight junctions. However, proinflammatory chemokine responses were similar for both cultures. Also, lambda IFNs, especially IL-29, were induced by RSV infection. Conclusions: RSV induced remarkably similar, albeit quantitatively lower, cytopathogenesis and proinflammatory responses in WD-PNECs compared with WD-PBECs that reproduce many hallmarks of RSV pathogenesis in infants. WD-PNECs may provide an authentic surrogate model with which to study RSV cytopathogenesis in infant airway epithelium.

28 July 2004 in Diabetologia
Verified
Journal Article
Closed access
PDF file
NAN. L. Alderson
N. L. Alderson
MCM. E. Chachich
M. E. Chachich
NFN. Frizzell
N. Frizzell
PCP. Canning
P. Canning
TMTom Metz
Tom Metz
STS. R. Thorpe
S. R. Thorpe

1 January 2007 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
PCPaul Canning
Paul Canning
JGJosephine V Glenn
Josephine V Glenn
DHDaniel K Hsu
Daniel K Hsu
FLFu-Tong Liu
Fu-Tong Liu
TGTom A Gardiner
Tom A Gardiner
Alan W StittAlan W Stitt
Alan W Stitt
Breakdown of the inner blood‐retinal barrier (iBRB) occurs early in diabetes and is central to the development of sight‐threatening diabetic macular edema (DME) as retinopathy progresses. In the current study, we examined how advanced glycation end products (AGEs) forming early in diabetes could modulate vasopermeability factor expression in the diabetic retina and alter inter‐endothelial cell tight junction (TJ) integrity leading to iBRB dysfunction. We also investigated the potential for an AGE inhibitor to prevent this acute pathology and examined a role of the AGE‐binding protein galectin‐3 (Gal‐3) in AGE‐mediated cell retinal pathophysiology. Diabetes was induced in C57/BL6 wild‐type (WT) mice and in Gal‐3−/− transgenic mice. Blood glucose was monitored and AGE levels were quantified by ELISA and immunohistochemistry. The diabetic groups were subdivided, and one group was treated with the AGE‐inhibitor pyridoxamine (PM) while separate groups of WT and Gal‐3−/− mice were maintained as nondiabetic controls. iBRB integrity was assessed by Evans blue assay alongside visualisation of TJ protein complexes via occludin‐1 immunolocalization in retinal flat mounts. Retinal expression levels of the vasopermeability factor VEGF were quantified using real‐time RT‐PCR and ELISA. WT diabetic mice showed significant AGE ‐immunoreactivity in the retinal microvasculature and also showed significant iBRB breakdown (P < .005). These diabetics had higher VEGF mRNA and protein expression in comparison to controls (P < .01). PM‐treated diabetics had normal iBRB function and significantly reduced diabetes‐mediated VEGF expression. Diabetic retinal vessels showed disrupted TJ integrity when compared to controls, while PM‐treated diabetics demonstrated near‐normal configuration. Gal‐3−/− mice showed significantly less diabetes‐mediated iBRB dysfunction, junctional disruption, and VEGF expression changes than their WT counterparts. The data suggests an AGE‐mediated disruption of iBRB via upregulation of VEGF in the diabetic retina, possibly modulating disruption of TJ integrity, even after acute diabetes. Prevention of AGE formation or genetic deletion of Gal‐3 can effectively prevent these acute diabetic retinopathy changes.

13 June 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
PCPaul Canning
Paul Canning
BKBridget-Ann Kenny
Bridget-Ann Kenny
VPVivien Prise
Vivien Prise
JGJosephine Glenn
Josephine Glenn
MSMosharraf H. Sarker
Mosharraf H. Sarker
Alan W StittAlan W Stitt
Alan W Stitt
Significance: Breakdown of the blood–retinal barrier (BRB) is central to diabetic macular edema (DME). Here, we demonstrate that lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) plays a critical role in diabetes-related retinal vasopermeability, a response that is mediated by lysophosphatidylcholine (LPC). Because neutralization of VEGF is the current gold-standard treatment for DME, we assessed suboptimal systemic treatment of an Lp-PLA 2 inhibitor alongside a suboptimal intravitreal injection with a rat-specific VEGF antibody and demonstrated that protection against diabetes-mediated retinal vasopermeability was additive. We have also shown a coalescence of the LPC and VEGF pathways in retinal vascular endothelium via a common VEGF receptor 2-mediated mechanism. Alongside currently administered anti-VEGF agents, Lp-PLA 2 may be a useful therapeutic target for DME.

28 February 2007 in Diabetologia
Verified
Journal Article
Open access
PDF file
JHJ. M. Hughes
J. M. Hughes
EKE. J. Kuiper
E. J. Kuiper
IKIngeborg Klaassen
Ingeborg Klaassen
PCP. Canning
P. Canning
Alan W StittAlan W Stitt
Alan W Stitt
Reinier O. SchlingemannReinier O. Schlingemann
Reinier O. Schlingemann
Referred to as CCN, the family of growth factors consisting of cystein-rich protein 61 (CYR61, also known as CCN1), connective tissue growth factor (CTGF, also known as CCN2), nephroblastoma overexpressed gene (NOV, also known as CCN3) and WNT1-inducible signalling pathway proteins 1, 2 and 3 (WISP1, −2 and −3; also known as CCN4, −5 and −6) affects cellular growth, differentiation, adhesion and locomotion in wound repair, fibrotic disorders, inflammation and angiogenesis. AGEs formed in the diabetic milieu affect the same processes, leading to diabetic complications including diabetic retinopathy. We hypothesised that pathological effects of AGEs in the diabetic retina are a consequence of AGE-induced alterations in CCN family expression. CCN gene expression levels were studied at the mRNA and protein level in retinas of control and diabetic rats using real-time quantitative PCR, western blotting and immunohistochemistry at 6 and 12 weeks of streptozotocin-induced diabetes in the presence or absence of aminoguanidine, an AGE inhibitor. In addition, C57BL/6 mice were repeatedly injected with exogenously formed AGE to establish whether AGE modulate retinal CCN growth factors in vivo. After 6 weeks of diabetes, Cyr61 expression levels were increased more than threefold. At 12 weeks of diabetes, Ctgf expression levels were increased twofold. Treatment with aminoguanidine inhibited Cyr61 and Ctgf expression in diabetic rats, with reductions of 31 and 36%, respectively, compared with untreated animals. Western blotting showed a twofold increase in CTGF production, which was prevented by aminoguanidine treatment. In mice infused with exogenous AGE, Cyr61 expression increased fourfold and Ctgf expression increased twofold in the retina. CTGF and CYR61 are downstream effectors of AGE in the diabetic retina, implicating them as possible targets for future intervention strategies against the development of diabetic retinopathy.